July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
Key Points
Key points are not available for this paper at this time.
Abstract
The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Laurent Peyrin–Biroulet
University of Rome Tor Vergata
J
J. Casey Chapman
Baton Rouge General
Jean‐Frédéric Colombel
Semmelweis University
Journals
New England Journal of Medicine
Actions
Institutions
Inserm
University of Calgary
McGill University Health Centre
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...